Evidence map›Paper›PMID 35579111›Full record

ArticleThoracic cancer2022

Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study.

Bo Zhang, Xingya Li, Zhiyong Ma, Shucai Zhang, Xia Song, Hongjun Gao, Liqun Gong, Yi Hu, Mengzhao Wang, Da Jiang and 10 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 2 countries.

Bo ZhangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Xingya LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhiyong MaDepartment of Internal Medicine, Henan Cancer Hospital, Zhengzhou, China.
Shucai ZhangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Xia SongDepartment of Respiratory Medicine, Shanxi Provincial Cancer Hospital, Taiyuan, China.
Hongjun GaoDepartment of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.ORCID 0000-0001-5277-4292
Liqun GongDepartment of Pulmonary Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Yi HuDepartment of Medical Oncology, Chinese PLA General Hospital, Beijing, China.
Mengzhao WangDepartment of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China.
Da JiangDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang, China.
Cuiying ZhangDepartment of Medical Oncology, Inner Mongolia People's Hospital, Hohhot, China.
Xuedong YuanDepartment of Oncology, Peking University Third Hospital Yanqing Hospital, Beijing, China.
Baoshan CaoDepartment of Oncology, Peking University Third Hospital, Beijing, China.
Peng ZhangDepartment of Thoracic Surgery, General Hospital of Tianjin Medical University, Tianjin, China.
Ligong NieDepartment of Respiratory, Peking University First Hospital, Beijing, China.
Yuhui ZhangDepartment of Respiratory, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-4373-1845
Xiaoyan ChenDepartment of Medical Oncology, Beijing Shunyi Hospital, Beijing, China.
Lei HanDepartment of Medical Oncology, People's Hospital of Beijing Daxing District, Beijing, China.
Wenqiang WeiDepartment of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yuankai ShiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.ORCID 0000-0002-3342-4964
Chinese Academy of Medical Sciences & Peking Union Medical College · CNPeking University · CNCapital Medical University · CNChinese PLA General Hospital · CNBeijing Hospital · CNFirst Affiliated Hospital of Zhengzhou University · CNHebei Medical University · CNHenan Cancer Hospital · CNInner Mongolia People's Hospital · CNShanxi Provincial Cancer Hospital · CNShunyi Hospital of Beijing Traditional Chinese Medicine Hospital · CNTianjin Medical University Cancer Institute and Hospital · CNTianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPain is a fearful yet common symptom among lung cancer patients. This multicenter, cross-sectional study was conducted to examine the current status of pain prevalence and management in lung cancer patients in northern China.

methodsA total of 18 hospitals across northern China were selected. Patients with primary lung cancer who visited the outpatient clinic or were admitted in the wards on a preplanned day were invited to complete a questionnaire. Meanwhile, physicians who had experience of treating primary lung cancer patients were also surveyed.

resultsA total of 533 patients and 197 physicians provided valid responses to the survey, of which 45.4% (242/533) of patients reported pain during the course of disease and 24.2% (129/533) of patients had experienced pain within the past 24 h. The mean average pain intensity by the brief pain inventory was 3.47 ± 1.55. The binary logistic regression analysis showed female gender and stage IV disease were significantly associated with the presence of pain. A total of 74.4% (96/129) of patients reporting pain within 24 h were taking analgesics. The most common reason for patients not using analgesics was that the pain was tolerable (48.2%), while the most common barriers to prescribing opioids as reported by physicians were fear of adverse reactions (43.7%) and fear of addiction (43.1%).

conclusionDespite recognition of the importance of pain control by most physicians and an improvement in cancer pain management, inadequate treatment of cancer pain still exists in lung cancer patients in northern China. High-quality pain education for both patients and physicians is needed in the future.

Indexed as

Lung NeoplasmsPainAnalgesicsChinaCross-Sectional StudiesFemaleHumansPrevalenceAnalgesicscancer painlung cancerpain managementprevalencesurvey

Identifiers

PMID35579111
PMCPMC9161334
OpenAlexW4280582435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.